SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.59 | $0 | -$17M |
| 2026 Q1 | -0.69 | $0 | -$14M |
| 2025 Q4 | -0.38 | $0 | -$10M |
| 2025 Q3 | 0.00 | $0 | -$9M |